Assessing the association between dipeptidyl peptidase-4 inhibitors use and celiac disease through drug adverse event reporting

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Li, Dandan
    • Other Affiliation: Capital Medical University
  • Silvester, Jocelyn Anne
    • Other Affiliation: Boston Children’s Hospital
  • Crowley, Matthew J.
    • Other Affiliation: Duke University School of Medicine
  • Yang, Jeff Y.
    • Affiliation: Gillings School of Global Public Health, Department of Epidemiology
  • Alexopoulos, Anastasia-Stefania
    • Other Affiliation: Duke University School of Medicine
  • Xu, Yang
    • Other Affiliation: Peking University
  • Zhan, Siyan
    • Other Affiliation: Peking University
  • Wang, Tiansheng
    • Affiliation: Gillings School of Global Public Health, Department of Epidemiology
Abstract
  • Dipeptidyl peptidase 4 (DPP4) enzyme is an endoprotease that removes N-terminal prolines from intestinal peptides. These peptides include glucagon-like peptide-1 (GLP-1), which, as one of the main human incretin hormones produced by the gastrointestinal system, enhances insulin secretion in a glucose-dependent manner. Inhibition of DPP4 thus raises GLP-1 levels and has a glucose-lowering effect.
Date of publication
Keyword
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
License
  • Attribution-NonCommercial 4.0 International
Journal title
  • Therapeutic Advances in Chronic Disease
Journal volume
  • 11
Language
  • English
Version
  • Publisher
Funder
  • National Institutes of Health, NIH; National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK: T32 DK007760; Health Services Research and Development, HSR&D: CDA 13-261, T32 DK007634, T32DK007012
ISSN
  • 2040-6223
Publisher
  • SAGE Publications Ltd

Relations

Parents:

This work has no parents.

In Collection:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details 2040622320904301.pdf 2022-02-08 Public Download